A Proof of Concept Study to Determine the Efficacy of Entresto™ in HFpEF Based on Circulating Neprilysin Levels: The Circulating NEP and NEP Inhibition (CNEPi) Study
Phase of Trial: Phase IV
Latest Information Update: 08 May 2019
Price : $35 *
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Heart failure
- Focus Biomarker; Proof of concept; Therapeutic Use
- Acronyms CNEPi
- 03 May 2019 Planned End Date changed from 30 Apr 2019 to 1 Dec 2019.
- 03 May 2019 Planned primary completion date changed from 30 Mar 2019 to 1 Dec 2019.
- 03 Oct 2018 Status changed from not yet recruiting to recruiting.